Dr Djekidel is an American board certified physician in nuclear medicine. He graduated from the University of Michigan one of the pioneer institutions in nuclear medicine and the beacon of the development of MIBG and NP-59 among many other discoveries as well as a leading institution in hybrid imaging and radionuclide therapies. He also practiced for a number of years at another ivy league institution-Yale University-, where he was director of the nuclear medicine fellowship, and clinical lead for nuclear medicine epilepsy imaging and the molecular imaging clinical trials tumor metrics program.
He is a graduate of the SNMMI’s Future leaders’ academy, a lead author of the SNMMI Amyloid Imaging Guidelines published jointly by the SNMMI and EANM and a graduate of the AUR-AGFA Radiology Management Program and the AUR-Philips Academic Faculty Development Program.
Dr Djekidel is Division Chief of Nuclear Medicine and Molecular Imaging at Sidra Medicine. He is leading the Ictal EMU molecular imaging service that provides the latest SPECT and PET quantitative imaging for epilepsy patients at Sidra. He is striving to expand appropriate radionuclide therapy use in Qatar. He serves as a reviewer and associate editor for several journals and has had numerous speaking engagements, presentations, abstracts as well as peer reviewed published manuscripts. He has been a PI or co PI on several intramural and extramural translational as well as clinical grants. He has mentored the future generations of nuclear medicine specialists clinically and for their grants. He serves on several international SNMMI committees and has presented a number of CE/CME sessions at SNMMI meetings. He has a keen interest in neuro-nuclear imaging clinically and in the research arena. He also focuses on improving the appropriate clinical use of advanced techniques in nuclear medicine including semi-quantitative and hybrid imaging techniques in the diagnostic and therapeutic arenas.